EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Worldwide population prevalence and impact of sub‐diagnostic gastrointestinal symptoms

Olafur S Palsson iD, Jan Tack, Douglas A Drossman, Boris Le Nevé iD, Laurent Quinquis, Rim Hassouna, Johannah Ruddy iD, Carolyn B Morris, Ami D Sperber iD, Shrikant I Bangdiwala, Magnus Simrén

Alimentary Pharmacology & Therapeutics · 2024-04 · 59 (7) · 852-864

DOI: 10.1111/apt.17894 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 04.02.2024. Verfasst von Olafur S Palsson und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Quality of Life, Gastrointestinal Diseases. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Danone Nutricia Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Rome Foundation Global Epidemiology Study (RFGES) found that 40.3% of adults in 26 internet‐surveyed countries met Rome IV criteria for disorders of gut–brain interaction (DGBI). However, additional people not meeting DGBI criteria may also be burdened by frequent gastrointestinal symptoms.

Aims

To explore the prevalence and demographic distribution of sub‐diagnostic gastrointestinal symptoms, and the hypothesised associated effects on quality of life (QoL), life functioning and healthcare needs.

Methods

We analysed data from the RFGES survey, which included the Rome IV diagnostic questionnaire and QoL, psychological, work productivity and healthcare questions.

Results

Of the 50,033 people without a history of organic gastrointestinal disorders, 25.3% classified in the sub‐diagnostic group (no DGBI but one or more frequent gastrointestinal symptoms), 41.4% had DGBI and 33.4% had no frequent gastrointestinal symptoms (non‐GI group). Sub‐diagnostic prevalence in different world regions ranged from 22.2% (North America) to 30.5% (Middle East), was slightly higher among males than females and decreased with age. The sub‐diagnostic group was intermediate between the non‐GI and DGBI groups, and significantly different from both of them on QoL, anxiety, depression, somatisation, healthcare utilisation and life and work impairment.

Conclusions

One in four adults without organic gastrointestinal disorders or DGBI report frequent gastrointestinal symptoms. This sub‐diagnostic group has reduced QoL, greater psychological and non‐GI bodily symptoms, impaired work productivity and life activities and greater healthcare use compared to non‐GI individuals. This suggests that many in this sub‐diagnostic group might benefit from healthcare services or symptom self‐management advice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeGastrointestinal DiseasesAdultMaleFemaleHumansPrevalenceSurveys and QuestionnairesNorth America

Stichwörter der Autor:innen

Rome criteriaepidemiologygastrointestinal symptoms

Autor:innen und Institutionen

  • University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.
  • University of North Carolina at Chapel Hill and CEO of the Rome Foundation, Raleigh, North Carolina, USA.
  • Danone Nutricia Research, Gif-sur-Yvette, France.
  • The Rome Foundation, Raleigh, North Carolina, USA.
  • Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

ORCID-Profile: Olafur S Palsson, Boris Le Nevé, Johannah Ruddy, Ami D Sperber

Förderung

  • Danone Nutricia Research

Zitieren

APA

Palsson, O. S., Tack, J., Drossman, D. A., Le Nevé, B., Quinquis, L., Hassouna, R., Ruddy, J., Morris, C. B., Sperber, A. D., Bangdiwala, S. I., & Simrén, M. (2024). Worldwide population prevalence and impact of sub‐diagnostic gastrointestinal symptoms. Alimentary Pharmacology & Therapeutics, 59(7), 852-864. https://doi.org/10.1111/apt.17894

Vancouver

Palsson OS, Tack J, Drossman DA, Le Nevé B, Quinquis L, Hassouna R, et al. Worldwide population prevalence and impact of sub‐diagnostic gastrointestinal symptoms. Alimentary Pharmacology & Therapeutics. 2024;59(7):852-864. doi:10.1111/apt.17894

BibTeX
@article{Palsson2024,
  author = {Palsson, Olafur S and Tack, Jan and Drossman, Douglas A and Le Nevé, Boris and Quinquis, Laurent and Hassouna, Rim and Ruddy, Johannah and Morris, Carolyn B and Sperber, Ami D and Bangdiwala, Shrikant I and Simrén, Magnus},
  title = {Worldwide population prevalence and impact of sub‐diagnostic gastrointestinal symptoms},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {59},
  number = {7},
  pages = {852--864},
  doi = {10.1111/apt.17894}
}
Kostenlos starten →